Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

239
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
239
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

224
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
224
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

33
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
33
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

387
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
387
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

310
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
310

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New proteomic biomarkers identified in plasma extracellular vesicles in sarcoidosis: a case-control matched study.

Frontiers in immunology·2026
Same author

Sarcoidosis: Disease mechanisms, diagnostic pathway and treatment.

Autoimmunity reviews·2026
Same author

Diagnostic accuracy of echocardiography in identifying heart failure related pleural effusions.

Respiratory medicine·2026
Same author

Short- and Long-Term Survival in Patients with Idiopathic Pulmonary Fibrosis and Muscle Loss.

Respiration; international review of thoracic diseases·2025
Same author

Signal regulating proteins (SIRPs) participate in sarcoidosis granuloma formation by promoting immune cell aggregation.

Respiratory research·2025
Same author

Clinical Approach to a Pleural Effusion.

Chest·2025

Related Experiment Video

Updated: Sep 12, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K

Can sarcoidosis be cured?

Paolo Spagnolo1, Marc A Judson2

  • 1Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.

Current Opinion in Immunology
|August 10, 2025
PubMed
Summary
This summary is machine-generated.

Pulmonary sarcoidosis outcomes vary greatly. Identifying specific sarcoidosis phenotypes may reveal new ways to achieve disease termination, potentially reducing reliance on corticosteroids.

More Related Videos

Diagnosis and Surgical Treatment of Human Brucellar Spondylodiscitis
06:23

Diagnosis and Surgical Treatment of Human Brucellar Spondylodiscitis

Published on: May 23, 2021

4.9K
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

49

Related Experiment Videos

Last Updated: Sep 12, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K
Diagnosis and Surgical Treatment of Human Brucellar Spondylodiscitis
06:23

Diagnosis and Surgical Treatment of Human Brucellar Spondylodiscitis

Published on: May 23, 2021

4.9K
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

49

Area of Science:

  • Pulmonary Medicine
  • Immunology
  • Rheumatology

Background:

  • Sarcoidosis is a systemic granulomatous disease with variable pulmonary involvement.
  • Clinical outcomes range from mild to life-threatening, with spontaneous or treatment-induced remission occurring.
  • Corticosteroids are first-line treatment but carry significant toxicity risks.

Purpose of the Study:

  • To explore factors influencing sarcoidosis disease termination.
  • To identify specific sarcoidosis phenotypes associated with better resolution rates.
  • To investigate potential alternative therapeutic strategies for sarcoidosis.

Main Methods:

  • Analysis of clinical course and outcomes in pulmonary sarcoidosis patients.
  • Evaluation of demographic factors, presentation modes, organ involvement, and disease duration.
  • Review of existing literature on sarcoidosis treatment and disease resolution.

Main Results:

  • Pulmonary sarcoidosis exhibits highly variable clinical courses and outcomes.
  • Disease resolution rates differ based on patient demographics, presentation, affected organs, and duration.
  • Certain sarcoidosis phenotypes demonstrate a higher likelihood of spontaneous or treatment-induced termination.

Conclusions:

  • Minimizing corticosteroid use is crucial due to toxicity.
  • Specific sarcoidosis phenotypes may predict disease termination.
  • Further research into these phenotypes could uncover novel immunopathogenic mechanisms for disease resolution.